Biogen

Biogen is a biotechnology company founded in 1978 by notable scientists, including Nobel laureates Walter Gilbert and Phillip Allen Sharp. The company focuses on developing innovative therapies for serious neurological, autoimmune, and rare diseases. Biogen is publicly traded on NASDAQ under the ticker symbol BIIB and is part of major stock indices like the S&P 500. Biogen develops and markets therapies primarily in neurology, including treatments for multiple sclerosis, spinal muscular atrophy, and Alzheimer’s disease. The company also offers therapies for autoimmune diseases such as rheumatoid arthritis and psoriasis, as well as treatments for genetic and rare neurological disorders. Biogen emphasizes advancing first-in-class therapies that improve patient outcomes through innovative science and technology. Its customers include patients, healthcare providers, and payers, and the company collaborates with research institutions to enhance drug development.